Abstract
Diffuse large B-cell lymphoma and Burkitt lymphoma are two distinct lymphoma entities recognized by the current World Health Organization classification of lymphoid neoplasms. Although diagnostic criteria to distinguish these two subtypes have been established, a subset of cases have overlapping characteristics and therefore, the distinction can be challenging. Thus, the World Health Organization classification introduced an intermediate subtype referred as "B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma". This review summarizes our current understanding of the biology of these lymphoma subtypes.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Burkitt Lymphoma / classification
-
Burkitt Lymphoma / drug therapy
-
Burkitt Lymphoma / genetics*
-
Burkitt Lymphoma / mortality
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / administration & dosage
-
Doxorubicin / therapeutic use
-
Gene Expression Profiling
-
Gene Expression Regulation, Neoplastic*
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / classification
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / genetics*
-
Lymphoma, Large B-Cell, Diffuse / mortality
-
Neoplasm Proteins / genetics*
-
Neoplasm Proteins / metabolism
-
Prednisone / administration & dosage
-
Prednisone / therapeutic use
-
Prognosis
-
Rituximab
-
Survival Analysis
-
Vincristine / administration & dosage
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Neoplasm Proteins
-
R-CHOP protocol
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone